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Abstract
Rate of FEV1 decline in COPD is heterogeneous and the extent to which inhaled corticosteroids (ICS) influence the
rate of decline is unclear. The majority of previous reviews have investigated specific ICS and non-ICS inhalers and
have consisted of randomised control trials (RCTs), which have specific inclusion and exclusion criteria and short
follow up times. We aimed to investigate the association between change in FEV1 and ICS-containing medications
in COPD patients over longer follow up times.
MEDLINE and EMBASE were searched and literature comparing change in FEV1 in COPD patients taking ICS-
containing medications with patients taking non-ICS-containing medications were identified. Titles, abstract, and full
texts were screened and information extracted using the PICO checklist. Risk of bias was assessed using the
Cochrane Risk of Bias tool and a descriptive synthesis of the literature was carried out due to high heterogeneity of
included studies.
Seventeen studies met our inclusion criteria. We found that the difference in change in FEV1 in people using ICS
and non-ICS containing medications depended on the study follow-up time. Shorter follow-up studies (1 year or
less) were more likely to report an increase in FEV1 from baseline in both patients on ICS and in patients on non-
ICS-containing medications, with the majority of these studies showing a greater increase in FEV1 in patients on
ICS-containing medications. Longer follow-up studies (greater than 1 year) were more likely to report a decline in
FEV1 from baseline in patients on ICS and in patients on non-ICS containing medications but rates of FEV1 decline
were similar.
Further studies are needed to better understand changes in FEV1 when ICS-containing medications are prescribed
and to determine whether ICS-containing medications influence rate of decline in FEV1 in the long term. Results
from inclusive trials and observational patient cohorts may provide information more generalisable to a population
of COPD patients.
Keywords: Lung function, COPD, Inhaled corticosteroids, Review
Background
Chronic obstructive pulmonary disease (COPD) is a pro-
gressive disease characterized by the chronic obstruction
of airflow in the airways and lungs. Evidence based clin-
ical NICE guidelines recommend the use of inhaled
bronchodilators such as long-acting beta-2 adrenergic
receptor agonists (LABA) or long-acting muscarinic-
receptor antagonists (LAMA) for COPD maintenance
therapy [1, 2]. Currently, the addition of inhaled cortico-
steroids (ICS) is reserved for those who remain breathless
or exacerbate despite taking short-acting bronchodilators
(SABA) following NICE guidelines [3]. GOLD guidelines
suggest initial treatment of ICS should be reserved for pa-
tients in GOLD group D alongside LABA if blood eosino-
phil levels are greater than 300cells/μl. In addition,
combination ICS (ICS/LABA) should be considered in pa-
tients who exacerbate if blood eosinophil levels are greater
than 300 or 100 if they experience at least 2 moderate ex-
acerbations or a hospitalization from AECOPD or remain
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breathless [4]. However, the use of ICS for the treatment
of COPD has been debated.
FEV1 is a common measure used to assess lung func-
tion and multiple studies show FEV1 declines at a faster
rate in smokers compared to non-smokers [5]. Rando-
mised control trials (RCTs) have found that inhaled cor-
ticosteroids (ICS) reduce the rate of FEV1 decline in
people with COPD [6–9]. However, the rate of FEV1 de-
cline is heterogeneous and can vary depending on fac-
tors such as smoking status, exacerbations of COPD
(AECOPD), and season [10, 11]. Most RCTs compare
COPD patients on a specific ICS to those on a placebo,
have specific inclusion and exclusion criteria and com-
monly exclude participants based on age, comorbidities
and severity of disease [12]. In addition, most studies
have short follow-up periods of less than 1 year. There-
fore, most RCTs are not easily generalisable to the wider
COPD population over the longer term.
Previous literature reviews have consisted of pre-
specified ICS and non-ICS comparators [13–18] such as
LAMA/LABA vs LABA/ICS or ICS, LAMA/LABA vs
LABA, LAMA or LABA/ICS and more specific compari-
sons such as budesonide or beclomethasone vs placebo.
Several large scale RCTs investigating various ICS and
FEV1 decline have taken place since, such as the Study
to Understand Mortality and Morbidity in COPD (SUM-
MIT) and the Withdrawal of Inhaled Steroids during
Optimized Bronchodilator Management (WISDOM) tri-
als, justifying the need to inform and summarise novel
findings. We aimed to investigate the association be-
tween ICS or ICS-containing medications and FEV1 de-
cline compared to non-ICS-containing medications in
COPD and determine whether length of follow-up influ-
ences the difference in FEV1 decline between ICS and
non-ICS containing groups.
Material and methods
The systematic review protocol was registered with the
International Prospective Register of Systematic Reviews
(PROSPERO), registration number: CRD42018090741.
For further detail on study protocol see study protocol
in Additional file 1.
Literature search
We systematically searched MEDLINE and EMBASE
(up until the 25th April 2019) using the following key
words:
1) COPD (Chronic Obstructive Pulmonary Disease);
COAD (Chronic Obstructive Airways Disease);
obstructive airflow/airway/lung/pulmonary/
respiratory/bronchiectasis; emphysema; chronic
bronchitis.
2) Inhaled corticosteroids; inhaled budesonide/
fluticasone/beclomethasone/momentasone/
flunisolide/ciclesonide.
3) Forced expiratory volume; lung function;
respiratory function tests; FEV1; change/rate/
decline/worse/reduce/decrease/slow FEV1/lung
function/lung volume.
Searched terms included medical subject headings and
free text words (see study protocol in Additional file 1).
The Boolean operator “or” was used to search terms
within the three concepts above and the operator “and”
was used to combine the three concepts. Only English
language literature was searched.
Selection of studies
We included studies that had recruited people with
physician diagnosed COPD or an FEV1/FVC < 70% who
were aged 35 or older and were current or ex-smokers.
Articles were included if the exposure and comparison
were ICS-containing medications and non-ICS-
containing medications and if they reported a change in
FEV1 over time for both exposure and comparison
groups. Change from baseline FEV1 was defined as
change in post-bronchodilator FEV1. Articles were ex-
cluded if they included people with diagnosed asthma or
asthma-COPD overlap syndrome.
Two reviewers (HW and MS) independently screened
all titles and abstracts following the inclusion criteria
and compared initial included titles. Any inconsistencies
were discussed and if necessary, a third party intervened.
This was repeated for full text articles. Conference pa-
pers, non-English language papers, review articles, proto-
cols, or systematic reviews were not included.
Data extraction, quality assessment and data synthesis
Data was extracted following predetermined criteria base
on the PICO checklist. Study details included: study
name; patient number; length of follow-up; study inclu-
sion and exclusion criteria; population characteristics in-
cluding recruitment method, gender, and mean age;
non-ICS comparison; ICS type and dosage; crude and
adjusted outcome (change in FEV1); statistical analysis;
and any additional notes. Two reviewers extracted rele-
vant data, which were compared and inconsistencies
discussed.
Quality of studies was assessed using the Cochrane
Risk of Bias Tool. This was developed to assess a RCTs
external and internal validity [19]. This tool assesses se-
lection bias, reporting bias, performance bias, detection
bias, attrition bias, and biases not identified in the previ-
ous categories. Quality of studies were reported as high,
moderate, or low bias.
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A meta-analysis was performed to investigate treat-
ment differences in change in FEV1 between ICS and
non-ICS containing medications (Additional file 1: Fig-
ure S1). Treatment differences were calculated using t-
tests [20]. Due to high heterogeneity (I2 = 98.9%; P <
0.0001) a descriptive synthesis was performed. Data were
described with regards to type of ICS-containing medi-
cations, type of comparator, length of study follow-up
and population characteristics.
Results
Four thousand four hundred fifty-four studies were iden-
tified in MEDLINE (n = 1319) and EMBASE (n = 3135)
following the electronic systematic search. After dupli-
cate articles were excluded 3353 article titles and ab-
stracts were screened of which, 181 articles were
selected for full text screening. Seventeen articles met
our inclusion criteria illustrated in the PRISMA flow-
chart (Fig. 1). One hundred sixty-four articles were ex-
cluded (see Fig. 1 for further details).
Study characteristics
All studies that met our inclusion criteria were RCTs
(Table 1). Examples of RCTs that met our inclusion cri-
teria included: ISOLDE (Inhaled Steroids in Obstructive
Lung Disease in Europe), TRINITY, SUMMIT and
TRISTAN (Trial of Inhaled Steroids and long-acting β2
Agonists).
Included studies were published between 1991 to
2018; spanning a 27 year period. The number of patients
included in studies ranged from 24 participants [21] to
16,485 patients [6, 35]. The majority of studies had high
numbers of recruited males. The percentage of females
in studies ranged from 0% [30] to 46% [25] and the me-
dian percentage of females included was 25.5%. The
mean age of included participants ranged from approxi-
mately 53 years [33] to 67 years [23]. The median length
of follow-up ranged from 3months [21–23] to 4 years
[6, 35].
Studies differed by types of ICS and non-ICS medica-
tions. The most common comparison was placebo vs
ICS. Other comparisons included LABA vs LABA/ICS,
placebo vs LABA/ICS, LABA vs ICS, and LAMA vs
LAMA/ICS. Tables 1 and 2 illustrate all types of ICS
and non-ICS comparisons in more detail.
Change in FEV1
Table 1 illustrates the change in FEV1, by study and or-
dered by length of study follow-up, showing a high degree
of variation between studies. A large proportion of the
variation was dependent on study follow-up time and type
of comparison. Change in FEV1 in studies that had less
than one year of follow-up varied between − 120ml
(standard deviation [SD] 230) to + 163ml (95% confidence
intervals [CI] 80 to 245) over 3months in non-ICS con-
taining medications and between -13ml (CI − 59 to 33) to
+ 239ml (CI 183 to 296) over 3months in ICS-containing
medication [21, 22, 24]. Change in FEV1 in studies that
had more than one year of follow-up varied between -69
ml/year to 21ml/year (CI 3 to 39) in non-ICS containing
medications and between -57ml/year to 85ml/year (CI 31
to 110) in ICS-containing medications [27, 33].
Fig. 1 PRISMA flowchart illustrating selection process of articles
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Study follow-up time
Figure 2 illustrates change in FEV1 in ICS and non-ICS-
containing medications in studies with follow-up of one
year or less. The majority of ICS point estimates show
an increase in FEV1 and 8 out of 10 studies showed that
change in FEV1 increased more or decreased slower in
ICS groups compared to non-ICS groups.
Figure 3 illustrates change in FEV1 in ICS and non-
ICS-containing medications in studies with follow-up
greater than one year in ml/year. All studies showed a
decline in FEV1 in both ICS and non-ICS groups, of
which there was little difference in FEV1 decline between
the two groups.
The general trend in change in FEV1 with increasing
follow-up time suggests that greater increases with ICS-
containing medications are seen in short term studies up
to approximately one year. Longer studies greater than a
year show that FEV1 generally declines over time. All
studies with greater than 1 year of follow-up were placebo
vs ICS comparisons.
Inclusion and exclusion criteria
Common inclusion criteria included specific criteria re-
garding age, smoking status and disease severity. Specif-
ically, the majority of studies included patients aged 40
years old or older. In terms of smoking status, the
majority of studies included current or ex-smokers with
at least 10 pack years history smoking. Nearly all studies
included patients with an FEV1/FVC < 70%. FEV1%
predicted criteria was commonly 30–70% predicted
or < 50%.
Furthermore, 4 studies required at least one AECOPD
prior to the start of follow-up. These included moderate
or severe AECOPD requiring prescribed oral corticoste-
roids and/or antibiotics or have been hospitalised for
AECOPD prior to the start of the study. One study spe-
cifically required no AECOPD prior to study start. Other
inclusion criteria included MRC dyspnea scores of 2 or
more, FEV1 reversibility, and risk or history of cardiovas-
cular disease. Additional file 1: Table S1 shows detailed
inclusion criteria by study.
The most common exclusion criteria was the presence
of diagnosed comorbidities including other respiratory
diseases (e.g. asthma, pneumonia, URTI, LRTI) and clin-
ically significant diseases that could affect results and pa-
tient participation (e.g. MI, HF, angina, and diabetes).
Further exclusion criteria included long-term oxygen
therapy, evidence of alcoholism or solvent abuse,
AECOPD requiring prescription of oral corticosteroid,
antibiotics, or hospitalisation prior to study start or
Table 2 ICS and non-ICS-containing medication comparisons
Type of ICS-containing medication Type of non-ICS containing medication Number of studies
Placebo ICS 13
Fluticasone propionate 3
Budesonide 6
Fluticasone furoate 2
Beclomethasone 1
Triamicinolone acetonide 1
LABA LABA/ICS 5
Salmeterol Salmeterol/fluticasone proprionate 3
Vilanterol Vilanterol/fluticasone furoate 2
Placebo LABA/ICS 3
Vilanterol/fluticasone furoate 2
Salmeterol/fluticasone proprionate 1
LABA ICS 3
Vilanterol Fluticasone furoate 2
Salmeterol Fluticasone proprionate 1
LAMA LAMA/ICS 2
Tiotropium Glycopyyronium/beclomethasone/fluticasone proprionate 1
Tiotropium Tiotropium/beclothmethasone/fluticasone proprionate 1
LAMA LAMA+ LABA/ICS 1
Tiotopium Tiotropium + formaterol/budesonide 1
Notes: numbers do not add up to the total number of studies included in the systematic review due to multiple ICS or non-ICS containing medications used in some studies.
Medications in bold indicate higher level subgroups of ICS and non-ICS containing medications
Abbreviations: ICS Inhaled corticosteroid, LABA Long acting beta-agonist, LAMA Long acting muscarinic antagonist
Whittaker et al. Respiratory Research          (2019) 20:277 Page 7 of 12
moderate/severe AECOPDs. Additional exclusion cri-
teria are shown in Additional file 1: Table S1.
Quality assessment
The majority of studies were considered low risk in each
of the bias domains. Reasons for considering ‘random se-
quence and allocation concealment’ unclear was due to
no mention of a sequence generator in text or in add-
itional files. ‘Reporting bias’ and ‘other biases’ were low
risk because all outcomes mentioned in the methods
were reported in the results. Similarly, no other biases
were found in all studies. ‘Performance and detection
bias’ was considered unclear in the study by Cazzola and
colleagues [22] because the authors failed to report
whether and how the study participants and personnel
were blinded during follow-up and outcome assess-
ment. ‘Performance and detection bias’ was considered
high risk in the study by Lee and colleagues [23] as par-
ticipants and personnel were not blinded during the
study. The study by Shaker and colleagues [36] was
considered to have unclear ‘attrition bias’ because there
was no indication whether only participants with
complete follow-up were used to measure change in
FEV1. High risk ‘attrition bias’ was observed in 4
studies. This was because only participants with
complete follow-up (i.e. completed the study and did
not dropout) were included in the analysis. See Add-
itional file 1: Figure S2 and Quality Assessment for
quality assessment by risk of bias domain and support
for judgment.
Discussion
This systematic review investigated the change in FEV1
with ICS-containing medications compared to non-ICS-
containing medications in COPD patients over the short
and long term. Of the 17 studies that met our inclusion
criteria, all were RCTs. We found that the majority of
studies with less than a year follow-up reported increases
in FEV1, with the general trend favouring ICS medica-
tions compared to non-ICS medications. Studies with
more than a year follow-up generally reported a decline
in FEV1 with little evidence of a treatment difference be-
tween ICS and non-ICS containing medications.
Length of study follow-up
Our main finding suggests that initiating ICS medica-
tions improves lung function compared to non-ICS
medications however, over long periods of time lung
Fig. 2 Change in FEV1 (ml) in studies with follow-up of one year or less. Studies are ordered by follow-up time. Note: Confidence intervals were
not shown if the study did not report them or they were unable to be calculated
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function declines at a similar rate in both ICS and non-
ICS medications. This may be due to an initial acute
bronchodilation, [37] or subtle improvements in care in
both arms shortly after recruitment. The decline in FEV1
in studies greater than a year is seen in both ICS and
non-ICS containing medications and raises the question
of whether ICS-containing medications are similar to
non-ICS medications over long periods of time with re-
spect to their effect on lung function. In addition, the
studies that reported a significant difference between the
changes in FEV1 favouring ICS-containing medications
were studies that were less than 1 year in duration.
Type of ICS-containing medications and comparators
We found that in terms of rate of change of FEV1 per
year, the majority of studies compared: i) placebos to
monotherapy ICS; ii) LABA to LABA/ICS; iii) placebo to
LABA/ICS; iv) LABA to monotherapy ICS; and v)
LAMA to LAMA+LABA/ICS.
Previous literature suggests that ICS/LABA has better
outcomes in COPD compared to the use of ICS mono-
therapy or LABA monotherapy. ICS/LABA is associated
with reduced rate of AECOPD, improved FEV1 and im-
proved patient health status compared to its individual
components [38]. Barnes and colleagues showed that
monotherapy ICS does not suppress inflammation in
COPD [39, 40]. Further studies show that the anti-
inflammatory effect of ICS is greater in the presence of
beta agonists and help increase the number of beta-
receptors and improve bronchodilation from LABA [41,
42]. Four studies in our systematic review included ICS/
LABA as the ICS comparison arm. FEV1 improved in
ICS/LABA groups compared to its non-ICS comparator
whereas monotherapy ICS showed a decline in FEV1,
similar to its non-ICS comparator. However, all stud-
ies investigating monotherapy ICS compared to a
non-ICS medication had a follow-up greater than one
year and all but one study investigating ICS/LABA
had a follow-up of less than one year. All studies that
compared ICS/LABA to LABA or ICS/LAMA to
LAMA showed that FEV1 improved more in ICS
combination groups compared to LABA or LAMA.
Therefore, whilst improvement in FEV1 was seen in
LABA and LAMA groups, the addition of ICS im-
proved lung function further, highlighting the initial
beneficial effect of ICS.
Furthermore, recently it has been suggested that the
use of LAMA/LABA is preferential over ICS/LABA in
COPD patients. This may be due to the synergistic effect
of LABA and LAMA which activate both adrenergic and
cholinergic pathways maximizing bronchodilation [43,
44]. A recent systematic review investigated the use of
LAMA/LABA compared to ICS/LABA and found that
compared to ICS/LABA, patients on LAMA/LABA had
improved health status, decreased moderate or severe
AECOPD, and decreased use of rescue medications [13,
16, 45]. Unfortunately, studies including LAMA/LABA
were not included in the final synthesis as they did not
Fig. 3 Change in FEV1 (ml/year) in studies with follow-up greater than one year. Studies are ordered by follow-up time. Note: Confidence
intervals were not shown if the study did not report them or they were unable to be calculated
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meet our inclusion criteria so we were unable to investi-
gate its effect on lung function compared to ICS/LABA.
Interestingly, the latest GOLD guidelines state that
ICS/LABA use should be considered if blood eosinophils
are greater than 300cells/μl in patients who exacerbate
more frequently, severely, and who are more breathless
[4]. Studies have shown that patients with high blood eo-
sinophils who initiate ICS respond better in terms of
lung function compared to those with low blood eosino-
phils [46]. On the other hand, observational studies have
shown no association over longer follow-up periods [47].
As the studies we included did not stratify by eosinophils
we were unable to look into this further however, further
literature reviews and meta-analyses should explore this
further.
Strengths and limitations
This is an extensive literature update comparing the
change in FEV1 between ICS-containing medications
and non-ICS containing medications over time. ICS-
containing medications were compared with non-ICS-
containing medications in order to be as inclusive as
possible and highlight differences in ICS type as well as
length of follow-up and other study characteristics. The
majority of studies included in this review had few biases
and were of good quality. In addition, clinical trials with
large patient populations such as TRISTAN, TRINITY,
ISOLDE, and SUMMIT were included in this review.
One limitation of this systematic review is that ICS
monotherapy was included even though it is not cur-
rently licensed in the UK [3, 48]. This is due to the risk
of developing pneumonia and no improvement in lung
function decline or risk of mortality compared to that of
LABAs [49–51]. Over time prescribing ICS monotherapy
has decreased [52] and it is advised by NICE that ICS
monotherapy should not be used for treatment of COPD
[48] . The majority of studies included reported a change
in lung function in patients on ICS monotherapy, but 7
of the 12 studies were published in 2000 or earlier. The
remaining studies that included ICS monotherapy were
published between 2001 and 2018. These studies were
either conducted in the United States or were multicen-
ter studies that included centers in countries across Eur-
ope, Africa, and the Americas. Changes in FEV1
reported in these studies should therefore be interpreted
with caution depending on the prescribing location.
Furthermore, whilst differences in change in FEV1 be-
tween ICS-containing medication and non-ICS-
containing medications were seen, they were not always
significant. This could have been due to small numbers
of recruited patients. In addition, not all studies reported
a treatment difference and it therefore unclear whether
these differences are statistically significant as well as
clinically significant. In those that did report statistical
treatment differences, not all were clinically significant
or vice versa. It has previously been suggested by the
American Thoracic Society and the European Respira-
tory Society that a minimal important difference in FEV1
between two treatments ranges from 100ml to 140ml
[53]. However, this is with regards to pharmacological
trials and individual FEV1 measurements rather than a
rate. In addition, it is important to note that clinically
important differences in the real world may be different
to those seen from RCTs.
Moreover, the results from included studies consist of
mostly crude changes in FEV1. Whilst it is important to
observe the range of crude changes with regards to ICS
and non-ICS containing medications, they could be
skewed by baseline FEV1. Milder patients with a higher
baseline FEV1 may have more lung function to lose
compared to a more severe patient with a lower baseline
FEV1 [54]. Using a measure of change that accounts for
baseline FEV1 may be more informative, such as percent
change from baseline.
In addition, all studies included were RCTs and had
many inclusion and exclusion criteria. All studies in-
cluded patients with moderate to very severe COPD.
Other common inclusion/exclusion criteria consisted
of specific pack year smoking history and no other
significant comorbidity. Whilst RCTs are important
due to their valuable methodological design, they are
typically not representative of the wider population of
COPD patients, many of whom have comorbidities.
Therefore, the representativeness of the results in-
cluded in this review should be noted. Observational
and general practice studies are needed to identify
changes in lung function in a more representative
COPD population with a wider degree of disease se-
verity and comorbid conditions.
Lastly, we observed a high level of heterogeneity be-
tween studies and therefore, a network meta-analysis
was not performed. This limited our ability to make con-
clusions on rate of change in FEV1 by ICS and non-ICS
comparisons.
Conclusion
The findings from this systematic review suggests that
in COPD patients, initiating ICS medications im-
proves lung function compared to non-ICS medica-
tions. However, over long periods of time lung
function declines at a similar rate for both ICS and
non-ICS medications. Further studies that are more
generalizable to the wider population of COPD pa-
tients are needed in order to investigate the associ-
ation between ICS and FEV1 decline further.
Additionally, studies with a longer follow-up are
needed to observe the long term effect of ICS on
lung function.
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Additional file
Additional file 1. Systematic review protocol; Figure S1: Meta-analysis
of treatment differences between ICS-containing medications and non-
ICS-containing medications, stratified by follow-up time; Table S1: Inclu-
sion and exclusion criteria of included studies; Figure S2: Quality assess-
ment of included studies. Quality assessment.
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